mild COVID-19 – Communicable Diseases Research

Antibiotic prescribing trends in the US during the first 11 months of the COVID-19 pandemic

Observational Study

Published on 2022-10-012022-10-04
Journal: Research in social & administrative pharmacy : RSA
[Category] 임상,

The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial

Article

Published on 2022-09-192022-11-16
Journal: International Journal of Environmental Research an
[Category] SARS, 치료기술,

Humoral and cellular immune response levels at a 1-year follow-up after mild COVID-19

가벼운 COVID-19 이후 1년 추적 관찰에서 체액 및 세포 면역 반응 수준

Article

Published on 2022-09-012022-09-11
Journal: Journal of Clinical Virology
[Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] antibody antibody levels cellular Cellular immune response COVID-19 detectable disease Follow-up IFN-γ immune response memory Mild mild COVID-19 Participants Patient Primary infection resolved SARS-CoV-2 T cells T-cell T-cell immune response.
[DOI] 10.1016/j.jcv.2022.105236 PMC 바로가기 [Article Type] Article

Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial

경증 COVID-19에서 입원으로의 진행을 예방하는 단일 용량 및 이중 용량 이버멕틴 조기 치료의 효능: 다군, 병렬 그룹, 무작위, 이중 맹검, 위약 대조 시험

Randomized Controlled Trial

Published on 2022-09-012022-09-11
Journal: Respirology (Carlton, Vic.)
[Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] absolute difference adverse event anti-parasitic Antiviral antiviral agent Clinical course clinical trial conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection dermatitis double-blind early treatment Efficacy enrolled evaluate Hospitalization hypertension investigated Ivermectin ivermectin group Mild mild COVID-19 mild COVID-19 patients Mild symptom mild symptoms multi-arm no significant difference parallel-group Patient Placebo placebo group placebo-controlled trial Primary outcome progression proportion proportions Randomized randomized clinical trial randomized clinical trial. receive required reverse transcription reverse transcription-PCR SARS-CoV-2 severity Severity Score Single-dose statistically significant subject Tachycardia
[DOI] 10.1111/resp.14318 PMC 바로가기 [Article Type] Randomized Controlled Trial

Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID-19

Article

Published on 2022-06-012023-07-08
Journal: European journal of neurology
[Category] COVID19(2023년),

[키워드] Cognitive difficulties executive functions fatigue mild COVID-19 primary motor cortex Transcranial magnetic stimulation.
[DOI] 10.1111/ene.15278 PMC 바로가기

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Randomized Controlled Trial

Published on 2022-04-012022-10-04
Journal: Clinical microbiology and infection : the official
[Category] 신약개발, 임상,

[키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome Admissions adverse events assigned clinical clinical recovery clinical trial coronavirus coronavirus disease COVID-19 did not reduce double-blind double-blinded enrolment evaluate Favipiravir hazard ratio Hospital admission Hospitalization intensive care interim analysis interquartile range male matching placebo median age median time Mild mild case mild COVID-19 mild COVID-19 patient monitoring board multicentre negative RT-PCR no difference Non-severe SARS-CoV-2 Non-severe SARS-CoV-2. participant Patient PCR test PCR-confirmed Placebo placebo-controlled clinical trial placebo-controlled trial Primary outcome Randomized receive recruited reduce reducing SARS-CoV-2 Saudi Arabia secondary outcome Seven severe adverse events symptom resolution the placebo group therapy Treatment treatment group Trial two group viral clearance
[DOI] 10.1016/j.cmi.2021.12.026 PMC 바로가기 [Article Type] Randomized Controlled Trial

Timely treatment and higher compliance to traditional Chinese medicine: New influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021

Research article

Published on 2022-04-012022-10-05
Journal: Pharmacological research
[Category] COVID19(2023년), SARS, 변종, 치료법,

[키워드] addition adhere age Antibiotics antiviral medicine association calculated changed characterized Chinese cohort study cohorts collected Compliance Concomitant medication conditions conducted control limit COVID-19 patient COVID-19 patients diagnosed Diagnosis disease E-value effective Effectiveness enrolled Epidemic Factor Final hospital Hospitalization Hospitalized incidence independent risk factor initial symptom initial symptoms LCL less measure Mild mild COVID-19 Moderate COVID-19 multivariate logistic regression New objective outcome participant Patient predict Prognosis progressed proportion public health reduced reducing Result retrospective cohort retrospective cohort study sensitivity analysis Severe case severe cases severe COVID-19 Severity of disease Sex TCM The proportion to severe status Traditional Chinese medicine treat Treatment were used Wuhan
[DOI] 10.1016/j.phrs.2022.106174 [Article Type] Research article

Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

Research article

Published on 2022-03-012022-10-05
Journal: Infectious diseases now
[Category] SARS, 변종,

Two months follow-up of patients with non-critical COVID-19 in Cape Town, South Africa

Original Research

Published on 2022-02-102022-10-29
Journal: South African Family Practice
[Category] COVID-19, COVID19(2023년), MERS, SARS,

Recruitment of highly cytotoxic CD8 + T cell receptors in mild SARS-CoV-2 infection

경증 SARS-CoV-2 감염에서 세포독성이 높은 CD8 + T 세포 수용체 모집

Article

Published on 2022-01-112022-09-11
Journal: Cell Reports
[Category] SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed Antigen CD8 CD8(+) T cells Combination convalescent individuals coronavirus Cytotoxic T cells cytotoxicity demonstrated epitope Epitopes feature functional gene signature gene signatures heterogeneous HLA human leukocyte antigen Immunity immunodominant infected cells Infection investigated leukocyte Mild mild COVID-19 mild SARS-CoV-2 infection polyclonal Protective protective immunity Quantitative recruited respiratory responses retrieved SARS-CoV-2 SARS-CoV-2 epitope SARS-COV-2 infection scRNA sequencing. Sequencing severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 T cell T cell immunity T cell receptor T cells TCR TCR engineering TCR identification TCRs virus-infected cells
[DOI] 10.1016/j.celrep.2021.110214 PMC 바로가기 [Article Type] Article